A December 2016 Judicial Panel for Multidistrict Litigation (JPML) Order Consolidated All Invokana And Invokamet Cases
In September 2016, pursuant to 28 U.S.C. § 1407, a motion was filed to establish IN RE: INVOKANA (CANAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION, MDL Docket No. 2750.
In October 2016 the attorneys for Defendant Janssen Pharmaceuticals, Inc. (“Janssen”) indicated, in their legal document filed as a response to this MDL motion, that all Invokana cases filed in the federal court system should be consolidated. Further, they agreed that federal Judge Brian Martinotti, of the District of New Jersey, would be an appropriate choice by the Judicial Panel for Multidistrict Litigation (JPML) for the so-called "transferee judge" presiding over this Invokana MDL.
In December 2016 the JPML issued an Order establishing this consolidation of all Invokana federal court lawsuits.
From a December 8, 2016 New Jersey Law Journal article, "Invokana Kidney Damage MDL Established in New Jersey" (free registration required), we get the following information about this legal case development:
The panel said in its order that the cases have enough in common to warrant centralization.
"On the basis of the papers filed and the hearing session held, we find that the Invokana/Invokamet actions involve common questions of fact, and that centralization of these cases will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation," the panel said. "The actions share factual questions arising from allegations that taking Invokana or Invokamet may result in patients suffering various injuries, including diabetic ketoacidosis and kidney damage. The actions thus implicate numerous common issues concerning the development, manufacture, testing, regulatory history, promotion, and labeling of the drugs."
The suits all claim that the diabetes drug causes kidney failure and a condition called diabetic ketoacidosis, which is caused by the buildup of acids in the blood.
Strictly Confidential, No Obligation.
Invokana (canagliflozin) was approved by the FDA in 2013.
Invokamet (canagliflozin and metformin) was approved by the FDA in 2014.
In December 2015 the FDA issued this Drug Safety Communication: “FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections”. In part, it warned about the risk of ketoacidosis, a serious medical condition caused by having too much acid in the blood, for a class of newer diabetes drugs which include Invokana and Invokamet. To read more, see our earlier article: "FDA Adds Ketoacidosis Warnings To Diabetes Drugs Invokana, Farxiga, And Jardiance As Well As Other SGLT2 Inhibitors".
In May and June 2016 the FDA announced it had strengthened the existing warning about the risk of acute kidney injury for Invokana and Invokamet. To read more, see our earlier article: "Invokana, Invokamet, Farxiga, Xigduo: Warnings About Acute Kidney Injury Risk Are Increased On Revised Drug Labels For These Diabetes Medicines".
In August 2016 the FDA sent letters to Janssen for Invokana and Invokamet label changes concerning fatal cases of ketoacidosis. To read more, see our earlier article: "FDA Mandates Label Change Warning About Fatal Cases Of Ketoacidosis For All Diabetes Drugs Known As Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors".
Lastly, we refer you to this earlier article, "Diabetes Medicine Invokana Gets New Warning About Lower Limb Amputation Added To Drug Package Insert In Canada". Interestingly, this December 2016 label change mandated by Health Canada did not apply to Jardiance, Farxiga, and the rest of the SGLT2 inhibitors class of drugs.
We are currently investigating possible Invokana and Invokamet lawsuits against the drug company Janssen for diabetes patients who have developed any of the medical conditions listed above.
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects (All website content by attorney Tom Lamb)
Drug Injury Case Evaluation - Free. Confidential. No Obligation. (Case review done by attorney Tom Lamb)